On February 11, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that management will be presenting at the BIO CEO & Investor Conference taking place February 16-18 (Press release, Infinity Pharmaceuticals, FEB 11, 2021, View Source [SID1234574913]). Presentations details are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BIO CEO & Investor Conference Presentation Details:
Date:

February 16 – 18

Presentation:

Available on demand starting February 16th at 10am EST

The link for the presentation will be available at www.infi.com.